OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
Owonikoko T, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Sadraei N, Shetty A, Smit M, Zhang Y, Sable B, Pati A, Roy S, Borghaei H. OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC. Journal Of Thoracic Oncology 2021, 16: s126. DOI: 10.1016/j.jtho.2021.01.313.Peer-Reviewed Original ResearchBispecific T-cell engagerT-cell engagers